Literature DB >> 16971466

IFN-gamma-activated monocytes weakly produce HIV-1 but induce the recruitment of HIV-sensitive T cells and enhance the viral production by these recruited T cells.

Héla Saïdi1, Giuliana Magri, Cedric Carbonneil, Nadine Nasreddine, Mary Réquena, Laurent Bélec.   

Abstract

The ability of macrophages to adapt to changing cytokine environments results in the dominance of a particular functional phenotype of macrophages, which would play a significant role in HIV pathogenesis. In comparison with untreated macrophages (M0), we examined the role of macrophages derived from IFN-gamma-activated monocytes (M1) in the HIV spread. We show that M0 and M1 bind with the same efficiency HIV-1 with a predominant role of C-type lectins in the R5-HIV attachment and of the heparan sulfate proteoglycans in the X4-HIV attachment. Despite similar levels of R5- and X4-HIV DNA, M1 replicates and weakly transmits the virus to activated T cells by releasing CXCR4- and CCR5-interacting chemokines. The blockade of dendritic cell-specific ICAM-3-grabbing nonintegrin expressed on M1 by mAb does not interfere with the viral transfer. Uninfected M1 recruits HIV-sensitive T cells efficiently and releases soluble factors, enhancing the viral production by these recruited cells. This study highlights the role of IFN-gamma to induce a population of macrophages that archive HIV-1 within a latent stage and cause the persistence of the virus by favoring the recruitment of T cells or enhancing the viral replication in infected CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971466     DOI: 10.1189/jlb.0406278

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Phenotype and functionality of CD4+ and CD8+ T cells in the upper reproductive tract of healthy premenopausal women.

Authors:  Uma Shanmugasundaram; J William Critchfield; Jane Pannell; Jean Perry; Linda C Giudice; Karen Smith-McCune; Ruth M Greenblatt; Barbara L Shacklett
Journal:  Am J Reprod Immunol       Date:  2013-12-06       Impact factor: 3.886

2.  Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization.

Authors:  Mohammad-Ali Jenabian; Héla Saïdi; Charlotte Charpentier; Hicham Bouhlal; Dominique Schols; Jan Balzarini; Thomas W Bell; Guido Vanham; Laurent Bélec
Journal:  AIDS Res Ther       Date:  2010-06-14       Impact factor: 2.250

3.  Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication.

Authors:  Michael A Schmid; Eva Harris
Journal:  PLoS Pathog       Date:  2014-12-04       Impact factor: 6.823

4.  Adaptive HIV-specific B cell-derived humoral immune defenses of the intestinal mucosa in children exposed to HIV via breast-feeding.

Authors:  Sandrine Moussa; Mohammad-Ali Jenabian; Jean Chrysostome Gody; Josiane Léal; Gérard Grésenguet; Alain Le Faou; Laurent Bélec
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

5.  Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-D-mannose specific plant lectins: implication for microbicide development.

Authors:  Hela Saïdi; Nadine Nasreddine; Mohammad-Ali Jenabian; Maxime Lecerf; Dominique Schols; Corinne Krief; Jan Balzarini; Laurent Bélec
Journal:  J Transl Med       Date:  2007-06-12       Impact factor: 5.531

6.  Pre-clinical development as microbicide of zinc tetra-ascorbo-camphorate, a novel terpenoid derivative: potent in vitro inhibitory activity against both R5- and X4-tropic HIV-1 strains without significant in vivo mucosal toxicity.

Authors:  Héla Saïdi; Mohammad-Ali Jenabian; Bernard Gombert; Charlotte Charpentier; Aurèle Mannarini; Laurent Bélec
Journal:  AIDS Res Ther       Date:  2008-06-03       Impact factor: 2.250

Review 7.  HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells.

Authors:  Charles R Rinaldo
Journal:  Scientifica (Cairo)       Date:  2013-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.